Anti-IL-5 biologics effective for up to two years in severe asthma: study
Registry study shows 14% of patients with severe eosinophilic disease are 'super-responders'
More than 80% of patients with severe asthma responded to anti-IL-5 biologics in a two-year follow-up study, with 14% of patients being 'super-responders' that have no residual manifestations of disease, a registry study shows.
However, predicting who will be a super-responder is difficult and 69% of those treated had residual disease, the Dutch researchers say.
Data for 114 patients with severe eosinophilic asthma treated with mepolizumab, reslizumab or benralizumab in the multicentre Registry of Adult
